First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation
Endoscopy · 01.12.2024 · 56 (S 01 S 01) · E563-E564
DOI: 10.1055/a-2344-7002 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endoscopy, erschienen am 01.12.2024. Verfasst von Apostolis Papaefthymiou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Cleveland Clinic London, London, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Intestinal Mucosa. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Gastroenterology, Cleveland Clinic London, London, United Kingdom of Great Britain and Northern Ireland.
- Clinica Colonial, Santiago, Chile.
ORCID-Profile: Apostolis Papaefthymiou, Benjamin Norton
Zitieren
APA
Papaefthymiou, A., Norton, B., Hoebel, P. B., Rodriguez Grunert, L., & Haidry, R. J. (2024). First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation. Endoscopy, 56(S 01 S 01), E563-E564. https://doi.org/10.1055/a-2344-7002
Vancouver
Papaefthymiou A, Norton B, Hoebel PB, Rodriguez Grunert L, Haidry RJ. First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation. Endoscopy. 2024;56(S 01 S 01):E563-E564. doi:10.1055/a-2344-7002
BibTeX
@article{Papaefthymiou2024,
author = {Papaefthymiou, Apostolis and Norton, Benjamin and Hoebel, Pablo Becerra and Rodriguez Grunert, Leonardo and Haidry, Rehan J},
title = {First clinical application of a novel duodenal mucosal ablation device for type 2 diabetes using radiofrequency vapor ablation},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {S 01 S 01},
pages = {E563--E564},
doi = {10.1055/a-2344-7002}
}
EUVIMED